{"transactions":[{"id":4620827,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-09-17T20:04:37.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":9233,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years."}],"balance_after":18466,"derivative":{"exercise_price":71.93,"expiration_date":"2035-01-16","underlying":"Common Stock","underlying_shares":9233},"source":{"system":"sec-edgar","filing":"0001205703-26-000030","document":"wk-form4_1789675474.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1205703/000120570326000030/wk-form4_1789675474.xml","form_type":"4"}},{"id":4620826,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-09-17T20:04:37.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":6477,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years."}],"balance_after":20356,"derivative":{"exercise_price":64.25,"expiration_date":"2034-07-14","underlying":"Common Stock","underlying_shares":6477},"source":{"system":"sec-edgar","filing":"0001205703-26-000030","document":"wk-form4_1789675474.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1205703/000120570326000030/wk-form4_1789675474.xml","form_type":"4"}},{"id":4620825,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-09-17T20:04:37.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":4551,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Beginning January 18, 2024, options become exercisable in 37 installments, with the first 25% vesting on July 14, 2024 and the remainder vesting monthly over three years."}],"balance_after":4551,"derivative":{"exercise_price":61.18,"expiration_date":"2034-01-17","underlying":"Common Stock","underlying_shares":4551},"source":{"system":"sec-edgar","filing":"0001205703-26-000030","document":"wk-form4_1789675474.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1205703/000120570326000030/wk-form4_1789675474.xml","form_type":"4"}},{"id":4620824,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-09-17T20:04:37.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":2957,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The July 14, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years."}],"balance_after":4225,"derivative":{"exercise_price":61.76,"expiration_date":"2033-07-13","underlying":"Common Stock","underlying_shares":2957},"source":{"system":"sec-edgar","filing":"0001205703-26-000030","document":"wk-form4_1789675474.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1205703/000120570326000030/wk-form4_1789675474.xml","form_type":"4"}},{"id":4620823,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Common Stock","published_at":"2026-09-17T20:04:37.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":13985,"price":120.49,"value":1685052.65,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested."}],"balance_after":183200,"source":{"system":"sec-edgar","filing":"0001205703-26-000030","document":"wk-form4_1789675474.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1205703/000120570326000030/wk-form4_1789675474.xml","form_type":"4"}},{"id":4620822,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Common Stock","published_at":"2026-09-17T20:04:37.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":9233,"price":120.5,"value":1112576.5,"ownership":{"direct":true},"balance_after":197185,"source":{"system":"sec-edgar","filing":"0001205703-26-000030","document":"wk-form4_1789675474.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1205703/000120570326000030/wk-form4_1789675474.xml","form_type":"4"}},{"id":4620821,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Common Stock","published_at":"2026-09-17T20:04:37.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":9233,"price":71.93,"value":664129.69,"ownership":{"direct":true},"balance_after":206418,"source":{"system":"sec-edgar","filing":"0001205703-26-000030","document":"wk-form4_1789675474.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1205703/000120570326000030/wk-form4_1789675474.xml","form_type":"4"}},{"id":4620820,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Common Stock","published_at":"2026-09-17T20:04:37.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":6477,"price":64.25,"value":416147.25,"ownership":{"direct":true},"balance_after":197185,"source":{"system":"sec-edgar","filing":"0001205703-26-000030","document":"wk-form4_1789675474.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1205703/000120570326000030/wk-form4_1789675474.xml","form_type":"4"}},{"id":4620819,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Common Stock","published_at":"2026-09-17T20:04:37.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":4551,"price":61.18,"value":278430.18,"ownership":{"direct":true},"balance_after":190708,"source":{"system":"sec-edgar","filing":"0001205703-26-000030","document":"wk-form4_1789675474.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1205703/000120570326000030/wk-form4_1789675474.xml","form_type":"4"}},{"id":4620818,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Common Stock","published_at":"2026-09-17T20:04:37.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":2957,"price":61.76,"value":182624.32,"ownership":{"direct":true},"balance_after":186157,"source":{"system":"sec-edgar","filing":"0001205703-26-000030","document":"wk-form4_1789675474.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1205703/000120570326000030/wk-form4_1789675474.xml","form_type":"4"}},{"id":680558,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Common Stock","published_at":"2026-08-20T21:15:28.000Z","date":"2026-08-19","kind":"sale","planned":true,"acquired":false,"shares":10801,"price":125.56,"value":1356173.56,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested."}],"balance_after":183200,"source":{"system":"sec-edgar","filing":"0001205703-26-000028","document":"wk-form4_1787260512.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000028/wk-form4_1787260512.xml","form_type":"4"}},{"id":687434,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Common Stock","published_at":"2026-08-14T20:01:01.000Z","date":"2026-08-12","kind":"sale","planned":true,"acquired":false,"shares":10803,"price":120.04,"value":1296792.12,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested."}],"balance_after":194001,"source":{"system":"sec-edgar","filing":"0001205703-26-000027","document":"wk-form4_1786737658.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000027/wk-form4_1786737658.xml","form_type":"4"}},{"id":693599,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Common Stock","published_at":"2026-08-07T20:02:23.000Z","date":"2026-08-05","kind":"sale","planned":true,"acquired":false,"shares":10640,"price":122.69,"value":1305421.6,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested."}],"balance_after":204804,"source":{"system":"sec-edgar","filing":"0001205703-26-000025","document":"wk-form4_1786132939.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000025/wk-form4_1786132939.xml","form_type":"4"}},{"id":698085,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Common Stock","published_at":"2026-08-04T20:04:23.000Z","date":"2026-07-31","kind":"sale","planned":true,"acquired":false,"shares":15888,"price":119.7,"value":1901793.6,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested."}],"balance_after":215444,"source":{"system":"sec-edgar","filing":"0001205703-26-000023","document":"wk-form4_1785873861.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000023/wk-form4_1785873861.xml","form_type":"4"}},{"id":706041,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-07-20T20:09:36.000Z","date":"2026-07-16","kind":"grant","planned":false,"acquired":true,"shares":57861,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.\nRemarks:"}],"balance_after":57861,"derivative":{"exercise_price":116.65,"expiration_date":"2036-07-15","underlying":"Common Stock","underlying_shares":57861},"source":{"system":"sec-edgar","filing":"0001205703-26-000021","document":"wk-form4_1784578174.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000021/wk-form4_1784578174.xml","form_type":"4"}},{"id":706040,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Performance Shares","published_at":"2026-07-20T20:09:36.000Z","date":"2026-07-16","kind":"grant","planned":false,"acquired":true,"shares":33508,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return (\"TSR\") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will\nvest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return (\"TSR\") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will\nvest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer."}],"balance_after":33508,"derivative":{"expiration_date":"2029-07-16","underlying":"Common Stock","underlying_shares":33508},"source":{"system":"sec-edgar","filing":"0001205703-26-000021","document":"wk-form4_1784578174.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000021/wk-form4_1784578174.xml","form_type":"4"}},{"id":706039,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Common Stock","published_at":"2026-07-20T20:09:36.000Z","date":"2026-07-16","kind":"grant","planned":false,"acquired":true,"shares":13403,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents award of restricted stock units (\"RSUs\") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Including the July 16, 2026 grant, this includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested."}],"balance_after":231332,"source":{"system":"sec-edgar","filing":"0001205703-26-000021","document":"wk-form4_1784578174.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000021/wk-form4_1784578174.xml","form_type":"4"}},{"id":708513,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Common Stock","published_at":"2026-07-16T20:08:16.000Z","date":"2026-07-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":4950,"price":115.09,"value":569695.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This includes an aggregate of 169,797 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested."}],"balance_after":217929,"source":{"system":"sec-edgar","filing":"0001205703-26-000019","document":"wk-form4_1784232493.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000019/wk-form4_1784232493.xml","form_type":"4"}},{"id":708512,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Common Stock","published_at":"2026-07-16T20:08:16.000Z","date":"2026-07-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":17969,"price":114.88,"value":2064278.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock."}],"balance_after":222879,"source":{"system":"sec-edgar","filing":"0001205703-26-000019","document":"wk-form4_1784232493.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000019/wk-form4_1784232493.xml","form_type":"4"}},{"id":753233,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Common Stock","published_at":"2026-06-03T20:58:30.000Z","date":"2026-06-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":25469,"price":95.59,"value":2434581.71,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This includes an aggregate of 213,078 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested."}],"balance_after":240848,"source":{"system":"sec-edgar","filing":"0001205703-26-000017","document":"wk-form4_1780520307.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000017/wk-form4_1780520307.xml","form_type":"4"}},{"id":770737,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Common Stock","published_at":"2026-05-20T20:01:39.000Z","date":"2026-05-06","kind":"grant","planned":false,"acquired":true,"shares":31517,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on May 6, 2026. The earned shares will vest on the third anniversary of the July 14, 2023 grant date, subject to the Reporting Person's continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, specified development, revenue and market-based (relative total shareholder returns compared to the Nasdaq Biotechnology Index) performance goals determined by the Issuer's Compensation Committee in January 2023 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three-year performance period ranges from 0% to 150% of the number of performance shares awarded."},{"field":"shares","element":"transactionShares","label":"F2","text":"This Form 4/A amends the original Form 4, filed on April 17, 2026, to reflect the Compensation Committee's determination on May 6, 2026 relating to the achievement of the performance criteria, which superseded the Compensation Committee's initial determination on April 15, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Including this certification of performance shares, this includes an aggregate of 261,178 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested."}],"balance_after":266317,"source":{"system":"sec-edgar","filing":"0001205703-26-000015","document":"wk-form4a_1779307294.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000015/wk-form4a_1779307294.xml","form_type":"4/A","original_submission_date":"2026-04-17"}},{"id":803990,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-21T20:09:07.000Z","date":"2026-04-17","kind":"exercise","planned":true,"acquired":false,"shares":12590,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years."}],"balance_after":27699,"derivative":{"exercise_price":71.93,"expiration_date":"2035-01-16","underlying":"Common Stock","underlying_shares":12590},"source":{"system":"sec-edgar","filing":"0001205703-26-000012","document":"wk-form4_1776802145.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000012/wk-form4_1776802145.xml","form_type":"4"}},{"id":803989,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-21T20:09:07.000Z","date":"2026-04-17","kind":"exercise","planned":true,"acquired":false,"shares":6077,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years."}],"balance_after":26833,"derivative":{"exercise_price":64.25,"expiration_date":"2034-07-14","underlying":"Common Stock","underlying_shares":6077},"source":{"system":"sec-edgar","filing":"0001205703-26-000012","document":"wk-form4_1776802145.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000012/wk-form4_1776802145.xml","form_type":"4"}},{"id":803988,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Common Stock","published_at":"2026-04-21T20:09:07.000Z","date":"2026-04-17","kind":"sale","planned":true,"acquired":false,"shares":18667,"price":96.5,"value":1801365.5,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This includes an aggregate of 257,553 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested."}],"balance_after":262692,"source":{"system":"sec-edgar","filing":"0001205703-26-000012","document":"wk-form4_1776802145.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000012/wk-form4_1776802145.xml","form_type":"4"}},{"id":803987,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Common Stock","published_at":"2026-04-21T20:09:07.000Z","date":"2026-04-17","kind":"exercise","planned":true,"acquired":true,"shares":12590,"price":71.93,"value":905598.7,"ownership":{"direct":true},"balance_after":281359,"source":{"system":"sec-edgar","filing":"0001205703-26-000012","document":"wk-form4_1776802145.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000012/wk-form4_1776802145.xml","form_type":"4"}},{"id":803986,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Common Stock","published_at":"2026-04-21T20:09:07.000Z","date":"2026-04-17","kind":"exercise","planned":true,"acquired":true,"shares":6077,"price":64.25,"value":390447.25,"ownership":{"direct":true},"balance_after":268769,"source":{"system":"sec-edgar","filing":"0001205703-26-000012","document":"wk-form4_1776802145.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000012/wk-form4_1776802145.xml","form_type":"4"}},{"id":806319,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Head of R&D"}}],"security":"Common Stock","published_at":"2026-04-17T20:12:54.000Z","date":"2026-04-15","kind":"grant","planned":false,"acquired":true,"shares":27892,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on April 15, 2026. The earned shares will vest on the third anniversary of the July 14, 2023 grant date, subject to the Reporting Person's continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, specified development, revenue and market-based (relative total shareholder returns compared to the Nasdaq Biotechnology Index) performance goals determined by the Issuers Compensation Committee in January 2023 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three-year performance period ranges from 0% to 150% of the number of performance shares awarded."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This includes an aggregate of 257,553 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested."}],"balance_after":262692,"source":{"system":"sec-edgar","filing":"0001205703-26-000010","document":"wk-form4_1776456771.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000010/wk-form4_1776456771.xml","form_type":"4"}},{"id":834093,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-03-19T20:20:22.000Z","date":"2026-03-17","kind":"exercise","planned":true,"acquired":false,"shares":11501,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years."}],"balance_after":32910,"derivative":{"exercise_price":64.25,"expiration_date":"2034-07-14","underlying":"Common Stock","underlying_shares":11501},"source":{"system":"sec-edgar","filing":"0001205703-26-000008","document":"wk-form4_1773951619.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000008/wk-form4_1773951619.xml","form_type":"4"}},{"id":834092,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-03-19T20:20:22.000Z","date":"2026-03-17","kind":"exercise","planned":true,"acquired":false,"shares":7166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Beginning January 18, 2024, options become exercisable in 37 installments, with the first 25% vesting on July 14, 2024 and the remainder vesting monthly over three years."}],"balance_after":9102,"derivative":{"exercise_price":61.18,"expiration_date":"2034-01-17","underlying":"Common Stock","underlying_shares":7166},"source":{"system":"sec-edgar","filing":"0001205703-26-000008","document":"wk-form4_1773951619.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000008/wk-form4_1773951619.xml","form_type":"4"}},{"id":834091,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-03-19T20:20:22.000Z","date":"2026-03-17","kind":"sale","planned":true,"acquired":false,"shares":18667,"price":94.24,"value":1759178.08,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This includes an aggregate of 229,661 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested."}],"balance_after":234800,"source":{"system":"sec-edgar","filing":"0001205703-26-000008","document":"wk-form4_1773951619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000008/wk-form4_1773951619.xml","form_type":"4"}},{"id":834090,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-03-19T20:20:22.000Z","date":"2026-03-17","kind":"exercise","planned":true,"acquired":true,"shares":11501,"price":64.25,"value":738939.25,"ownership":{"direct":true},"balance_after":253467,"source":{"system":"sec-edgar","filing":"0001205703-26-000008","document":"wk-form4_1773951619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000008/wk-form4_1773951619.xml","form_type":"4"}},{"id":834089,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-03-19T20:20:22.000Z","date":"2026-03-17","kind":"exercise","planned":true,"acquired":true,"shares":7166,"price":61.18,"value":438415.88,"ownership":{"direct":true},"balance_after":241966,"source":{"system":"sec-edgar","filing":"0001205703-26-000008","document":"wk-form4_1773951619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000008/wk-form4_1773951619.xml","form_type":"4"}},{"id":889149,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-23T21:05:14.000Z","date":"2026-02-19","kind":"exercise","planned":true,"acquired":false,"shares":5575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Beginning January 18, 2024, options become exercisable in 37 installments, with the first 25% vesting on July 14, 2024 and the remainder vesting monthly over three years."}],"balance_after":16268,"derivative":{"exercise_price":61.18,"expiration_date":"2034-01-17","underlying":"Common Stock","underlying_shares":5575},"source":{"system":"sec-edgar","filing":"0001205703-26-000006","document":"wk-form4_1771880710.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000006/wk-form4_1771880710.xml","form_type":"4"}},{"id":889148,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-23T21:05:14.000Z","date":"2026-02-19","kind":"exercise","planned":true,"acquired":false,"shares":13093,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The July 14, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years."}],"balance_after":7182,"derivative":{"exercise_price":61.76,"expiration_date":"2033-07-13","underlying":"Common Stock","underlying_shares":13093},"source":{"system":"sec-edgar","filing":"0001205703-26-000006","document":"wk-form4_1771880710.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000006/wk-form4_1771880710.xml","form_type":"4"}},{"id":889147,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-02-23T21:05:14.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":18668,"price":100.91,"value":1883787.88,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This includes an aggregate of 229,661 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested."}],"balance_after":234800,"source":{"system":"sec-edgar","filing":"0001205703-26-000006","document":"wk-form4_1771880710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000006/wk-form4_1771880710.xml","form_type":"4"}},{"id":889146,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-02-23T21:05:14.000Z","date":"2026-02-19","kind":"exercise","planned":true,"acquired":true,"shares":5575,"price":61.18,"value":341078.5,"ownership":{"direct":true},"balance_after":253468,"source":{"system":"sec-edgar","filing":"0001205703-26-000006","document":"wk-form4_1771880710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000006/wk-form4_1771880710.xml","form_type":"4"}},{"id":889145,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-02-23T21:05:14.000Z","date":"2026-02-19","kind":"exercise","planned":true,"acquired":true,"shares":13093,"price":61.76,"value":808623.68,"ownership":{"direct":true},"balance_after":247893,"source":{"system":"sec-edgar","filing":"0001205703-26-000006","document":"wk-form4_1771880710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000006/wk-form4_1771880710.xml","form_type":"4"}},{"id":934722,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-21T21:06:47.000Z","date":"2026-01-16","kind":"grant","planned":false,"acquired":true,"shares":28475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Beginning January 16, 2026, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2026 and the remainder vesting monthly over three years."}],"balance_after":28475,"derivative":{"exercise_price":106.21,"expiration_date":"2036-01-15","underlying":"Common Stock","underlying_shares":28475},"source":{"system":"sec-edgar","filing":"0001205703-26-000002","document":"wk-form4_1769029605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120570326000002/wk-form4_1769029605.xml","form_type":"4"}},{"id":1086986,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-07-16T20:05:57.000Z","date":"2025-07-15","kind":"grant","planned":false,"acquired":true,"shares":39471,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The July 15, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years."}],"balance_after":39471,"derivative":{"exercise_price":68.25,"expiration_date":"2035-07-14","underlying":"Common Stock","underlying_shares":39471},"source":{"system":"sec-edgar","filing":"0000879169-25-000086","document":"wk-form4_1752696353.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/879169/000087916925000086/wk-form4_1752696353.xml","form_type":"4"}},{"id":1086985,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Performance Shares","published_at":"2025-07-16T20:05:57.000Z","date":"2025-07-15","kind":"grant","planned":false,"acquired":true,"shares":43846,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return (\"TSR\") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return (\"TSR\") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer."}],"balance_after":43846,"derivative":{"expiration_date":"2028-07-15","underlying":"Common Stock","underlying_shares":43846},"source":{"system":"sec-edgar","filing":"0000879169-25-000086","document":"wk-form4_1752696353.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/879169/000087916925000086/wk-form4_1752696353.xml","form_type":"4"}},{"id":1086984,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2025-07-16T20:05:57.000Z","date":"2025-07-15","kind":"grant","planned":false,"acquired":true,"shares":17538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents award of restricted stock units (\"RSUs\") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Including the July 15, 2025 grant, this includes an aggregate of 229,661 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested."}],"balance_after":234800,"source":{"system":"sec-edgar","filing":"0000879169-25-000086","document":"wk-form4_1752696353.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879169/000087916925000086/wk-form4_1752696353.xml","form_type":"4"}},{"id":1086983,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2025-07-16T20:05:57.000Z","date":"2025-07-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":2628,"price":68.25,"value":179361.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock."}],"balance_after":217262,"source":{"system":"sec-edgar","filing":"0000879169-25-000086","document":"wk-form4_1752696353.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879169/000087916925000086/wk-form4_1752696353.xml","form_type":"4"}},{"id":1086982,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2025-07-16T20:05:57.000Z","date":"2025-07-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":1280,"price":69.98,"value":89574.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock."}],"balance_after":219890,"source":{"system":"sec-edgar","filing":"0000879169-25-000086","document":"wk-form4_1752696353.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879169/000087916925000086/wk-form4_1752696353.xml","form_type":"4"}},{"id":1298268,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-01-22T21:07:22.000Z","date":"2025-01-17","kind":"grant","planned":false,"acquired":true,"shares":40289,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years."}],"balance_after":40289,"derivative":{"exercise_price":71.93,"expiration_date":"2035-01-16","underlying":"Common Stock","underlying_shares":40289},"source":{"system":"sec-edgar","filing":"0000879169-25-000035","document":"wk-form4_1737580032.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879169/000087916925000035/wk-form4_1737580032.xml","form_type":"4"}},{"id":1453154,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-07-17T16:28:04.000Z","date":"2024-07-15","kind":"grant","planned":false,"acquired":true,"shares":44411,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years."}],"balance_after":44411,"derivative":{"exercise_price":64.25,"expiration_date":"2034-07-14","underlying":"Common Stock","underlying_shares":44411},"source":{"system":"sec-edgar","filing":"0000879169-24-000134","document":"wk-form4_1721233676.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879169/000087916924000134/wk-form4_1721233676.xml","form_type":"4"}},{"id":1453153,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2024-07-17T16:28:04.000Z","date":"2024-07-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":749,"price":64.25,"value":48123.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Including the July 15, 2024 grant, this includes an aggregate of 219,502 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested."}],"balance_after":221170,"source":{"system":"sec-edgar","filing":"0000879169-24-000134","document":"wk-form4_1721233676.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879169/000087916924000134/wk-form4_1721233676.xml","form_type":"4"}},{"id":1453152,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2024-07-17T16:28:04.000Z","date":"2024-07-15","kind":"grant","planned":false,"acquired":true,"shares":19851,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents award of restricted stock units (\"RSUs\") that will vest 25% annually over four years, subject to the employee's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis."}],"balance_after":221919,"source":{"system":"sec-edgar","filing":"0000879169-24-000134","document":"wk-form4_1721233676.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879169/000087916924000134/wk-form4_1721233676.xml","form_type":"4"}},{"id":1492549,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T17:31:34.000Z","date":"2024-06-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":141011,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."}],"balance_after":0,"derivative":{"exercise_price":2.35,"underlying":"Common Stock","underlying_shares":141011},"source":{"system":"sec-edgar","filing":"0000950170-24-068904","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024068904/ownership.xml","form_type":"4"}},{"id":1492548,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T17:31:34.000Z","date":"2024-06-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."}],"balance_after":0,"derivative":{"exercise_price":4.64,"underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0000950170-24-068904","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024068904/ownership.xml","form_type":"4"}},{"id":1492547,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T17:31:34.000Z","date":"2024-06-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."}],"balance_after":0,"derivative":{"exercise_price":3.6,"underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0000950170-24-068904","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024068904/ownership.xml","form_type":"4"}},{"id":1492546,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T17:31:34.000Z","date":"2024-06-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."}],"balance_after":0,"derivative":{"exercise_price":8.15,"underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0000950170-24-068904","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024068904/ownership.xml","form_type":"4"}},{"id":1492545,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T17:31:34.000Z","date":"2024-06-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the \"Arrangement Agreement\"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden (\"Parent\") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act (\"Purchaser\"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the \"Shares\") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the \"Effective Time\"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the \"Cash Consideration\") plus (ii) one contingent value right (each, a \"CVR\") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."}],"balance_after":0,"derivative":{"exercise_price":17,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-068904","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024068904/ownership.xml","form_type":"4"}},{"id":1674685,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-22T18:04:36.000Z","date":"2024-01-18","kind":"grant","planned":false,"acquired":true,"shares":21843,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Beginning January 18, 2024, options become exercisable in 37 installments, with the first 25% vesting on July 14, 2024 and the remainder vesting monthly over three years."}],"balance_after":21843,"derivative":{"exercise_price":61.18,"expiration_date":"2034-01-17","underlying":"Common Stock","underlying_shares":21843},"source":{"system":"sec-edgar","filing":"0000879169-24-000034","document":"wk-form4_1705946668.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879169/000087916924000034/wk-form4_1705946668.xml","form_type":"4"}},{"id":1828188,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-07-18T20:00:13.000Z","date":"2023-07-14","kind":"grant","planned":false,"acquired":true,"shares":20275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The July 14, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years."}],"balance_after":20275,"derivative":{"exercise_price":61.76,"expiration_date":"2033-07-13","underlying":"Common Stock","underlying_shares":20275},"source":{"system":"sec-edgar","filing":"0001209191-23-042551","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120919123042551/doc4.xml","form_type":"4"}},{"id":1828187,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2023-07-18T20:00:13.000Z","date":"2023-07-14","kind":"grant","planned":false,"acquired":true,"shares":9668,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents award of restricted stock units (\"RSUs\") that will vest 25% annually over four years, subject to Pablo Cagnoni's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Including the July 14, 2023 RSU Grant, this includes an aggregate of 202,068 shares of common stock issuable pursuant to previously reported RSUs that have not vested."}],"balance_after":202068,"source":{"system":"sec-edgar","filing":"0001209191-23-042551","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120919123042551/doc4.xml","form_type":"4"}},{"id":1848296,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2023-06-21T20:00:13.000Z","date":"2023-06-05","kind":"grant","planned":false,"acquired":true,"shares":192400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents award of restricted stock units (\"RSUs\") that will vest 25% annually over four years beginning June 1, 2026, subject to Pablo Cagnoni's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.  The original Form 4, filed on June 7, 2023, is being amended by this Form 4/A to correct an administrative error that incorrectly reported the number of units granted, originally reported as 179,613 instead of 192,400."}],"balance_after":192400,"source":{"system":"sec-edgar","filing":"0001209191-23-038745","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120919123038745/doc4a.xml","form_type":"4/A","original_submission_date":"2023-06-07"}},{"id":1856001,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-14T17:05:38.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option fully vests on the earlier of (i) June 14, 2024 or (ii) the 2024 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc."}],"balance_after":17000,"derivative":{"exercise_price":4.64,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-23-037090","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000120919123037090/doc4.xml","form_type":"4"}},{"id":1864506,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2023-06-07T18:00:08.000Z","date":"2023-06-05","kind":"grant","planned":false,"acquired":true,"shares":179613,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents award of restricted stock units (\"RSUs\") that will vest 25% annually over four years beginning June 1 2026, subject to Pablo Cagnoni's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis."}],"balance_after":179613,"source":{"system":"sec-edgar","filing":"0001209191-23-034977","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879169/000120919123034977/doc4.xml","form_type":"4"}},{"id":2038578,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-01T21:41:05.000Z","date":"2023-02-01","kind":"sale","acquired":false,"shares":8448,"price":0.25,"value":2112.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of restricted stock units for the Reporting Person, as previously disclosed on a Form 4 filed with the Securities and Exchange Commission on January 31, 2023. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the reporting person."}],"balance_after":66082,"source":{"system":"sec-edgar","filing":"0001104659-23-009465","document":"tm235103-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000110465923009465/tm235103-4_4seq1.xml","form_type":"4"}},{"id":2040379,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-01-31T21:51:39.000Z","date":"2023-01-31","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023."}],"balance_after":75000,"derivative":{"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-23-008874","document":"tm235103-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000110465923008874/tm235103-2_4seq1.xml","form_type":"4"}},{"id":2040378,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-01-31T21:51:39.000Z","date":"2023-01-29","kind":"exercise","acquired":false,"shares":21250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying the restricted stock units vest in four equal annual installments beginning on January 29, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying the restricted stock units vest in four equal annual installments beginning on January 29, 2022."}],"balance_after":42500,"derivative":{"underlying":"Common Stock","underlying_shares":21250},"source":{"system":"sec-edgar","filing":"0001104659-23-008874","document":"tm235103-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000110465923008874/tm235103-2_4seq1.xml","form_type":"4"}},{"id":2040377,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-31T21:51:39.000Z","date":"2023-01-31","kind":"sale","acquired":false,"shares":7240,"price":0.241,"value":1744.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.24 to $0.26, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":74530,"source":{"system":"sec-edgar","filing":"0001104659-23-008874","document":"tm235103-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000110465923008874/tm235103-2_4seq1.xml","form_type":"4"}},{"id":2040376,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-31T21:51:39.000Z","date":"2023-01-31","kind":"exercise","acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":81770,"source":{"system":"sec-edgar","filing":"0001104659-23-008874","document":"tm235103-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000110465923008874/tm235103-2_4seq1.xml","form_type":"4"}},{"id":2040375,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-31T21:51:39.000Z","date":"2023-01-29","kind":"exercise","acquired":true,"shares":21250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":56770,"source":{"system":"sec-edgar","filing":"0001104659-23-008874","document":"tm235103-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000110465923008874/tm235103-2_4seq1.xml","form_type":"4"}},{"id":2224237,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T19:05:53.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option fully vests on the earlier of (i) June 14, 2023 or (ii) the 2023 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc."}],"balance_after":17000,"derivative":{"exercise_price":3.6,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-22-038767","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000120919122038767/doc4.xml","form_type":"4"}},{"id":2398149,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2022-02-14T19:52:23.000Z","date":"2021-06-16","kind":"gift","acquired":false,"shares":2200,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":29320,"source":{"system":"sec-edgar","filing":"0001179110-22-001203","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000117911022001203/edgar.xml","form_type":"5"}},{"id":2398148,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2022-02-14T19:52:23.000Z","date":"2021-04-26","kind":"gift","acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":31520,"source":{"system":"sec-edgar","filing":"0001179110-22-001203","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000117911022001203/edgar.xml","form_type":"5"}},{"id":2419347,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2022-02-01T21:20:55.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023."}],"balance_after":100000,"derivative":{"underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001179110-22-000697","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000117911022000697/edgar.xml","form_type":"4"}},{"id":2419346,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-01T21:20:55.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":365000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of this option shall vest on January 31, 2023, then in 12 equal quarterly installments thereafter."}],"balance_after":365000,"derivative":{"exercise_price":6.75,"expiration_date":"2032-01-30","underlying":"Common Stock","underlying_shares":365000},"source":{"system":"sec-edgar","filing":"0001179110-22-000697","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000117911022000697/edgar.xml","form_type":"4"}},{"id":2419345,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2022-02-01T21:20:55.000Z","date":"2022-01-29","kind":"exercise","acquired":false,"shares":21250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying the restricted stock units vest in four equal annual installments beginning on January 29, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying the restricted stock units vest in four equal annual installments beginning on January 29, 2022."}],"balance_after":63750,"derivative":{"underlying":"Common Stock","underlying_shares":21250},"source":{"system":"sec-edgar","filing":"0001179110-22-000697","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000117911022000697/edgar.xml","form_type":"4"}},{"id":2419344,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2022-02-01T21:20:55.000Z","date":"2022-02-01","kind":"sale","acquired":false,"shares":6730,"price":6.573,"value":44236.29,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.57 to $6.72, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":35520,"source":{"system":"sec-edgar","filing":"0001179110-22-000697","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000117911022000697/edgar.xml","form_type":"4"}},{"id":2419343,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2022-02-01T21:20:55.000Z","date":"2022-01-29","kind":"exercise","acquired":true,"shares":21250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":42250,"source":{"system":"sec-edgar","filing":"0001179110-22-000697","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000117911022000697/edgar.xml","form_type":"4"}},{"id":2679489,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-07T16:13:45.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option fully vests on the earlier of (i) June 4, 2022 or (ii) the 2022 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc."}],"balance_after":17000,"derivative":{"exercise_price":8.15,"expiration_date":"2031-06-03","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-21-038567","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000120919121038567/doc4.xml","form_type":"4"}},{"id":2885863,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2021-02-02T20:26:53.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the restricted stock units will vest in four equal annual installments beginning on January 29, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying the restricted stock units will vest in four equal annual installments beginning on January 29, 2022."}],"balance_after":85000,"derivative":{"underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001179110-21-001126","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000117911021001126/edgar.xml","form_type":"4"}},{"id":2885862,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-02T20:26:53.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":375000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest on January 29, 2022, then in 12 equal quarterly installments thereafter."}],"balance_after":375000,"derivative":{"exercise_price":11.97,"expiration_date":"2031-01-28","underlying":"Common Stock","underlying_shares":375000},"source":{"system":"sec-edgar","filing":"0001179110-21-001126","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000117911021001126/edgar.xml","form_type":"4"}},{"id":3096760,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-30T06:36:00.000Z","date":"2020-06-25","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in 36 equal monthly installments beginning on July 18, 2020."}],"balance_after":30000,"derivative":{"exercise_price":17,"expiration_date":"2030-06-18","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-20-017873","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924320017873/doc4.xml","form_type":"4"}},{"id":3176546,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-04-15T17:14:47.000Z","date":"2020-04-14","kind":"purchase","acquired":true,"shares":21000,"price":4.6997,"value":98693.7,"ownership":{"direct":true},"balance_after":21000,"source":{"system":"sec-edgar","filing":"0001104659-20-047001","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000110465920047001/a4.xml","form_type":"4"}},{"id":3294988,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-03T21:48:52.000Z","date":"2020-01-31","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest on January 31, 2021, then in 12 equal quarterly installments thereafter."}],"balance_after":500000,"derivative":{"exercise_price":7.8,"expiration_date":"2030-01-30","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001104659-20-010064","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000110465920010064/a4.xml","form_type":"4"}},{"id":3363074,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-11-21T21:07:43.000Z","date":"2019-11-19","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on November 4, 2015 with respect to 93,833 Common Shares with 100% of the shares vesting in 48 equal monthly installments thereafter."}],"balance_after":63833,"derivative":{"exercise_price":5.59,"expiration_date":"2025-11-04","underlying":"Common Shares","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-19-057596","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919119057596/doc4.xml","form_type":"4"}},{"id":3363073,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-11-21T21:07:43.000Z","date":"2019-11-19","kind":"sale","acquired":false,"shares":7500,"price":62,"value":465000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-19-057596","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919119057596/doc4.xml","form_type":"4"}},{"id":3363072,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-11-21T21:07:43.000Z","date":"2019-11-19","kind":"exercise","acquired":true,"shares":7500,"price":5.59,"value":41925.0,"ownership":{"direct":true},"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001209191-19-057596","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919119057596/doc4.xml","form_type":"4"}},{"id":3372999,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-11-13T21:30:20.000Z","date":"2019-11-12","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on November 4, 2015 with respect to 93,833 Common Shares with 100% of the shares vesting in 48 equal monthly installments thereafter."}],"balance_after":71333,"derivative":{"exercise_price":5.59,"expiration_date":"2025-11-04","underlying":"Common Shares","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-19-056372","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919119056372/doc4.xml","form_type":"4"}},{"id":3372998,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-11-13T21:30:20.000Z","date":"2019-11-12","kind":"sale","acquired":false,"shares":7500,"price":55,"value":412500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-19-056372","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919119056372/doc4.xml","form_type":"4"}},{"id":3372997,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-11-13T21:30:20.000Z","date":"2019-11-12","kind":"exercise","acquired":true,"shares":7500,"price":5.59,"value":41925.0,"ownership":{"direct":true},"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001209191-19-056372","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919119056372/doc4.xml","form_type":"4"}},{"id":3383622,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-11-01T22:35:14.000Z","date":"2019-10-30","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on November 4, 2015 with respect to 93,833 Common Shares with 100% of the shares vesting in 48 equal monthly installments thereafter."}],"balance_after":78833,"derivative":{"exercise_price":5.59,"expiration_date":"2025-11-04","underlying":"Common Shares","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-19-054774","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919119054774/doc4.xml","form_type":"4"}},{"id":3383621,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-11-01T22:35:14.000Z","date":"2019-10-30","kind":"sale","acquired":false,"shares":7500,"price":52,"value":390000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-19-054774","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919119054774/doc4.xml","form_type":"4"}},{"id":3383620,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-11-01T22:35:14.000Z","date":"2019-10-30","kind":"exercise","acquired":true,"shares":7500,"price":5.59,"value":41925.0,"ownership":{"direct":true},"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001209191-19-054774","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919119054774/doc4.xml","form_type":"4"}},{"id":3491435,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-13T21:04:58.000Z","date":"2019-06-11","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 11, 2019 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2019; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2020 Annual General Meeting of Shareholders."}],"balance_after":15000,"derivative":{"exercise_price":43.52,"expiration_date":"2029-06-11","underlying":"Common Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-19-016845","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924319016845/doc4.xml","form_type":"4"}},{"id":3677664,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-04T18:34:15.000Z","date":"2019-01-31","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest on January 31, 2020, then in 12 equal quarterly installments thereafter."}],"balance_after":100000,"derivative":{"exercise_price":13.69,"expiration_date":"2029-01-30","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-19-005603","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000110465919005603/a4.xml","form_type":"4"}},{"id":3778172,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-01T20:11:36.000Z","date":"2018-10-31","kind":"grant","acquired":true,"shares":193400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon the achievement of a performance milestone, 50% of this option shall vest upon the achievement of a second performance milestone and 50% of this option shall vest upon the achievement of a third performance milestone."}],"balance_after":193400,"derivative":{"exercise_price":16.43,"expiration_date":"2028-10-30","underlying":"Common Stock","underlying_shares":193400},"source":{"system":"sec-edgar","filing":"0001104659-18-065519","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000110465918065519/a4.xml","form_type":"4"}},{"id":3778171,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-01T20:11:36.000Z","date":"2018-10-31","kind":"grant","acquired":true,"shares":164400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the achievement of a performance milestone, 25% of this option shall vest effective as of October 31, 2019, then in 12 equal quarterly installments thereafter."}],"balance_after":164400,"derivative":{"exercise_price":16.43,"expiration_date":"2028-10-30","underlying":"Common Stock","underlying_shares":164400},"source":{"system":"sec-edgar","filing":"0001104659-18-065519","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000110465918065519/a4.xml","form_type":"4"}},{"id":3872718,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-07-05T22:25:52.000Z","date":"2018-07-05","kind":"exercise","acquired":true,"shares":1684,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on November 4, 2015 with respect to 93,833 Common Shares with 100% of the shares vesting in 48 equal monthly installments thereafter."}],"balance_after":86333,"derivative":{"exercise_price":5.59,"expiration_date":"2025-11-04","underlying":"Common Shares","underlying_shares":1684},"source":{"system":"sec-edgar","filing":"0000899243-18-019501","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318019501/doc4.xml","form_type":"4"}},{"id":3872717,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-07-05T22:25:52.000Z","date":"2018-07-03","kind":"exercise","acquired":true,"shares":5816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on November 4, 2015 with respect to 93,833 Common Shares with 100% of the shares vesting in 48 equal monthly installments thereafter."}],"balance_after":88017,"derivative":{"exercise_price":5.59,"expiration_date":"2025-11-04","underlying":"Common Shares","underlying_shares":5816},"source":{"system":"sec-edgar","filing":"0000899243-18-019501","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318019501/doc4.xml","form_type":"4"}},{"id":3872716,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-07-05T22:25:52.000Z","date":"2018-07-05","kind":"sale","acquired":false,"shares":1684,"price":62,"value":104408.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-019501","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318019501/doc4.xml","form_type":"4"}},{"id":3872715,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-07-05T22:25:52.000Z","date":"2018-07-05","kind":"exercise","acquired":true,"shares":1684,"price":5.59,"value":9413.56,"ownership":{"direct":true},"balance_after":1684,"source":{"system":"sec-edgar","filing":"0000899243-18-019501","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318019501/doc4.xml","form_type":"4"}},{"id":3872714,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-07-05T22:25:52.000Z","date":"2018-07-03","kind":"sale","acquired":false,"shares":5816,"price":62,"value":360592.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-019501","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318019501/doc4.xml","form_type":"4"}},{"id":3872713,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-07-05T22:25:52.000Z","date":"2018-07-03","kind":"exercise","acquired":true,"shares":5816,"price":5.59,"value":32511.44,"ownership":{"direct":true},"balance_after":5816,"source":{"system":"sec-edgar","filing":"0000899243-18-019501","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318019501/doc4.xml","form_type":"4"}},{"id":3892654,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-16T01:35:52.000Z","date":"2018-06-15","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 15, 2018 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on May 30, 2018."}],"balance_after":15000,"derivative":{"exercise_price":59.31,"expiration_date":"2018-06-15","underlying":"Common Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-18-016868","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318016868/doc4.xml","form_type":"4"}},{"id":4295903,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-02T20:30:59.000Z","date":"2017-05-31","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 31, 2017 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning June 30, 2017."}],"balance_after":15000,"derivative":{"exercise_price":13.62,"expiration_date":"2027-05-31","underlying":"Common Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-17-015166","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924317015166/doc4.xml","form_type":"4"}},{"id":4576923,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":21401,"kind":"person","name":"CAGNONI PABLO J","position":1,"cik":"0001205703","reported_name":"CAGNONI PABLO J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-10-20T21:15:32.000Z","date":"2016-10-18","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on October 18, 2016 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning October 31, 2016."}],"balance_after":15000,"derivative":{"exercise_price":14,"expiration_date":"2026-10-18","underlying":"Common Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-16-032070","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924316032070/doc4.xml","form_type":"4"}}]}